Solid Biosciences

SLDBPhase 3

Solid Biosciences is a patient-centric, publicly traded biotech company dedicated to advancing a portfolio of gene therapy candidates for devastating rare diseases. Founded by those directly impacted by Duchenne muscular dystrophy, its mission is to improve patients' daily lives by uniting expertise in science, technology, and care. The company is advancing multiple programs in neuromuscular and cardiac diseases while developing enabling platform technologies to impact gene therapy delivery broadly. Solid emphasizes collaboration with stakeholders across industry, academia, and patient communities to accelerate the development of meaningful therapies.

Market Cap

$547.7M

Focus

BiologicsRNA & Gene TherapySmall Molecules

SLDB · Stock Price

USD 7.0311.72 (-62.51%)

Historical price data

AI Company Overview

Technology Platform

Developing innovative libraries of genetic regulators and other enabling technologies designed to significantly improve gene therapy delivery and control of transgene expression.

Pipeline Snapshot

3 drugs in pipeline, 1 in Phase 3

Drug	Indication	Stage
SGT-003 + Placebo	Duchenne Muscular Dystrophy	Phase 3
SGT-501	Catecholaminergic Polymorphic Ventricular Tachycardia	Phase 1
SGT-212	Friedreich's Ataxia (FA)	Phase 1

Opportunities

Solid's growth opportunities include successfully advancing its lead Duchenne program to market in a multi-billion dollar segment, expanding its pipeline into other rare neuromuscular and cardiac diseases with high unmet need, and leveraging its genetic regulator platform to enhance its own therapies or create partnership revenue through technology licensing.

Risk Factors

Key risks include clinical trial failures, particularly for lead asset SGT-003; intense competition in core markets like Duchenne; dependence on raising capital as a pre-revenue company; and the regulatory and commercialization challenges inherent in gene therapy development for rare diseases.

Competitive Landscape

Solid faces intense competition, especially in Duchenne from Sarepta Therapeutics (market leader), Pfizer, and Roche. In Friedreich's ataxia and genetic cardiac diseases, it competes with other gene therapy developers like Lexeo and Taysha. Differentiation will depend on demonstrating superior efficacy, safety, or delivery via its technology platform.

Publications

Pipeline